Toutes les études
Actif, mais pas en recrutementPHASE2, PHASE3INTERVENTIONNEL

A Study Evaluating the Efficacy and Safety of Mitapivat (AG-348) in Participants With Sickle Cell Disease (RISE UP)

This study, called RISE UP, is testing a new medicine called mitapivat for people with sickle cell disease. It has two main goals: first, to find the best dose of mitapivat, and second, to see how well it works and if it's safe. Specifically, researchers want to know if mitapivat can help increase the amount of a healthy red blood cell chemical (hemoglobin) in the blood and reduce painful episodes called sickle cell crises. Over time, the study will also look at the longer-term effects of this medicine. If you have sickle cell disease, this study could be an opportunity to explore a potential new treatment.

En un coup d'œil

Statut
Actif, mais pas en recrutement
Phase
PHASE2, PHASE3
Sponsor
Agios Pharmaceuticals, Inc.
Objectif d'inscription
286
Démarrer
11 fév. 2022
Achèvement estimé
01 févr. 2030

De quoi parle cette étude ?

Sickle cell disease is a lifelong condition that affects your red blood cells. Normally, these cells are round and flexible, carrying oxygen around your body. But with sickle cell disease, they can become stiff and C-shaped, like a farm tool called a sickle. These 'sickled' cells can block blood flow, leading to severe pain, called sickle cell crises, and other health problems.

This study is investigating a new medicine called mitapivat. It's designed to help your blood cells work better. The researchers want to find out the best amount of mitapivat to give and how well it helps people with sickle cell disease. They will be looking to see if it can increase healthy red blood cells and reduce the number of painful crises you might experience. It's important to remember that this is a research study, and we're still learning about this medicine.

The study is split into two main parts, called Phase 2 and Phase 3. The first part helps find the right dose. Then, a larger group of people will take part in Phase 3 to get a clearer picture of how effective and safe mitapivat is compared to a dummy pill (placebo). After these main parts, there's an option to continue taking mitapivat for a longer period to see its long-term effects.

Points clés

  • This study is testing a new medicine called mitapivat for sickle cell disease.
  • It aims to find the right dose and see if it helps increase red blood cells and reduce painful crises.
  • The study involves taking either mitapivat or a dummy pill (placebo).
  • Participation includes regular clinic visits and health checks.
  • Potential benefits might include access to a new treatment, but there are also potential side effects.
  • You can leave the study at any time without affecting your normal care.

Qui peut être éligible ?

To join this study, you need to be at least 16 years old. (In France and Germany, you must be 18 or older). If you're 16 or 17, you must have finished puberty. You need to have a clear diagnosis of sickle cell disease, including common types like HbSS or HbSC.

Over the past year, you should have experienced at least two, but no more than ten, painful sickle cell crises. Your haemoglobin level (a measure of your red blood cells) needs to be within a specific range. If you're currently taking a medicine called hydroxyurea, your dose must have been stable for at least 3 months. Women who could become pregnant must agree to use two types of birth control during the study.

There are also some reasons you wouldn't be able to join. For example, if you are pregnant or breastfeeding, or if you regularly receive blood transfusions. You would also be excluded if you have certain severe liver or kidney problems, or if you've had a stem cell transplant or gene therapy. Also, if you're taking certain other ongoing sickle cell medicines or investigational treatments, you might not be eligible.

Cet étude pourrait-elle vous convenir ?

Répondez à ces questions rapides pour voir si vous êtes éligible. Ceci est un guide uniquement — l'équipe de recherche prend la décision finale.

  1. Are you 16 years or older? (18+ in France/Germany)
  2. Do you have a diagnosis of sickle cell disease?
  3. Have you had 2 to 10 painful sickle cell crises in the last year?
  4. Are you able to use two forms of contraception if you could become pregnant?
  5. N'êtes-vous PAS enceinte ou en train d'allaiter ?
  6. Are you NOT regularly having blood transfusions?
Répondez à chaque question pour voir votre résultat.

En quoi consiste la participation ?

If you decide to take part, the study will involve several visits to a clinic. You'll be given either mitapivat or a dummy pill (placebo) to take. Initially, the study will involve different doses of mitapivat being tested in smaller groups. Then, in the main part, you'll either take the recommended dose of mitapivat or a placebo for about 52 weeks (roughly a year). This will be decided by chance, like flipping a coin. You won't know if you're getting the active medicine or the placebo, and neither will your local study doctor.

Throughout the study, you'll have regular checks, which might include blood tests, physical exams, and discussions about how you're feeling and any symptoms you have. The study team will explain all the procedures in detail. After the main part of the study, you might have the option to continue taking mitapivat for up to 216 weeks (over 4 years) in an open-label part, meaning everyone in this part would receive mitapivat.

Risques et avantages potentiels

Taking part in a study like this might offer some potential benefits, such as access to a new medicine that could improve your red blood cells and reduce pain, under close medical supervision. However, there are also potential risks; mitapivat might cause side effects, some of which we may not fully know yet. These will be explained to you in detail by the study team. You always have the right to leave the study at any time, for any reason, without it affecting your usual medical care.

Locations (91)

  • University of California San Diego
    Code postal vérifié
    La Jolla, United States
  • UCLA Health
    Code postal vérifié
    Los Angeles, États-Unis
  • Children's Hospital Oakland
    Code postal vérifié
    Oakland, États-Unis
  • University of Connecticut Health Center
    Code postal vérifié
    Farmington, United States
  • Children's National Hospital
    Code postal vérifié
    Washington D.C., États-Unis
  • MedStar Washington Hospital Center
    Code postal vérifié
    Washington D.C., États-Unis
  • Sylvester Comprehensive Cancer Center-Miami
    Code postal vérifié
    Miami, États-Unis
  • University of Chicago Medical Center
    Code postal vérifié
    Chicago, États-Unis
  • Riley Hospital For Children
    Code postal vérifié
    Indianapolis, États-Unis
  • LSU Health Sciences Center - Shreveport
    Code postal vérifié
    Shreveport, United States
  • National Heart Lung and Blood Institute
    Code postal vérifié
    Bethesda, United States
  • Kaiser Permanente - Largo Medical Center
    Code postal vérifié
    Largo, United States

Questions fréquentes

Qu'est-ce que la drépanocytose ?

It's a blood condition where red blood cells become stiff and C-shaped, causing pain and other health issues.

What is mitapivat?

It's a new medicine being tested to help make red blood cells healthier and reduce pain crises in people with sickle cell disease.

Qu'est-ce qu'un placebo ?

A placebo is a dummy pill that looks like the real medicine but contains no active ingredients. It helps researchers see if the real medicine is truly effective.

How long would I need to be in the study?

The main part of the study lasts about a year, with an option to continue for several more years afterwards.

Can I still take my regular medicines?

You might be able to, but some medicines need to be stopped or stable for a certain time before joining. The study team will tell you which ones.

Comment en savoir plus

Parlez toujours à votre médecin généraliste ou spécialiste avant de décider de participer à une étude.

Discussion

Discussion communautaire

Propulsé par notre forum à community.patient.info. Veuillez être respectueux — ceci n'est pas un avis médical.